Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBCSG 67-22 PREcoopERA
2022-503013-32-00Phase 2Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised trial in breast cancer comparing Giredestrant monotherapy, Giredestrant + triptorelin and Anastrozole + triptorelin (3 arms). Primary endpoint: Change in Ki-67 labeling index. Started Jan 2024; status: completed.
02
Drugs
giredestrantPamorelinanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-503013-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503013-32-00.